4.7 Review

Therapeutic implications of nanomedicine for ocular drug delivery

期刊

DRUG DISCOVERY TODAY
卷 24, 期 8, 页码 1524-1538

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.05.006

关键词

-

资金

  1. National Institutes of Health [R01EY027827]
  2. FDA [HHSF223201810114C]
  3. Ralph E. Powe Junior Faculty Award from Oak Ridge Associated Universities
  4. Center for Pharmaceutical Engineering and Sciences - School of Pharmacy, Virginia Commonwealth University
  5. Lowenthal Award for Graduate Research
  6. Blick Scholarship

向作者/读者索取更多资源

Delivering therapeutics to the eye is challenging on multiple levels: rapid clearance of eyedrops from the ocular surface requires frequent instillation, which is difficult for patients; transport of drugs across the blood-retinal barrier when drugs are administered systemically, and the cornea when drugs are administered topically, is difficult to achieve; limited drug penetration to the back of the eye owing to the cornea, conjunctiva, sclera and vitreous barriers. Nanomedicine offers many advantages over conventional ophthalmic medications for effective ocular drug delivery because nanomedicine can increase the therapeutic index by overcoming ocular barriers, improving drug-release profiles and reducing potential drug toxicity. In this review, we highlight the therapeutic implications of nanomedicine for ocular drug delivery.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据